Successful management of hepatitis B and C coinfection: a case report
DOI:
https://doi.org/10.47892/rgp.2024.443.1732Keywords:
Hepatitis B, Hepatitis C, Coinfection, Antiviral agentsAbstract
We report the case of a patient with chronic hepatitis B and C managed with direct-acting antivirals in an outpatient setting. Chronic hepatitis B was first treated with entecavir before initiating treatment for chronic hepatitis C. The patient achieved viral suppression for hepatitis B and sustained virological response for hepatitis C. As direct-acting antivirals become more available, healthcare practitioners should be familiar with managing patients with chronic coinfection.
Downloads
Metrics
References
Radley A, Robinson E, Aspinall EJ, Angus K, Tan L, Dillon JF. A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments. BMC Health Serv Res. 2019;19(1):765. doi: 10.1186/s12913-019-4635-7.
Shih Y-F, Liu C-J. Hepatitis C virus and hepatitis B virus coinfection. Viruses. 2020;12(7):741. doi: 10.3390/v12070741.
Wu J-C, Chen C-L, Hou M-C, Chen T-Z, Lee S-D, Lo K-J. Multiple viral infection as the most common cause of fulminant and subfulminant viral hepatitis in an area endemic for hepatitis B: Application and limitations of the polymerase chain reaction. Hepatology. 1994;19(4):836-40. doi: 10.1002/hep.1840190406.
Tyson GL, Kramer JR, Duan Z, Davila JA, Richardson PA, El-Serag HB. Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2013;58(2):538-45. doi: 10.1002/hep.26400.
Vaccination coverage among adults in the United States, National Health Interview Survey, 2021 [Internet]. Atlanta: Centers for Disease Control and Prevention; 2023 [cited 2024 May 18]. Available from: https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/vaccinationcoverage-adults-2021.html
Mavilia MG, Wu GY. HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation. J Clin Transl Hepatol. 2018;6(3):296-305. doi: 10.14218/JCTH.2018.00016.
Ma AT, Feld JJ. Hepatitis B reactivation with hepatitis C treatment: Bringing some clarity to the black box. Gastroenterology. 2018;154(4):795-8. doi: 10.1053/j.gastro.2018.02.005.
Terrault NA, Lok ASF, McMahon BJ, Chang K, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-99. doi: 10.1002/hep.29800.
American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV Guidance: Recommendations for testing, managing, and treating hepatitis C [Internet]. AASLD-IDSA; 2014 [cited 2024 May 18]. Available from: http://www.hcvguidelines.org
Wang C, Ji D, Chen J, Shao Q, Li B, Liu J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol. 2017;15(1):132-136. doi: 10.1016/j.cgh.2016.06.023.
Jiang XW, Ye JZ, Li YT, Li LJ. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis. World J Gastroenterol. 2018;24(28):3181-3191. doi: 10.3748/wjg.v24.i28.3181.
Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: A systematic review and meta-analysis. Clin Infect Dis. 2016;62(6):683-694. doi: 10.1093/cid/civ948.
Weksler BB. Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther. 2007;26 Suppl 1:13-9. doi: 10.1111/j.1365-2036.2007.03512.x.
Soliman Z, El Kassas M, Elsharkawy A, Elbadry M, Hamada Y, ElHusseiny R, et al. Improvement of platelet in thrombocytopenic HCV patients after treatment with direct-acting antiviral agents and its relation to outcome. Platelets. 2020;32(3):383-90. doi: 10.1080/09537104.2020.1742313.
Rockey DC, Friedman SL. Fibrosis regression after eradication of hepatitis C virus: From bench to bedside. Gastroenterology. 2021;160(5):1502-1520.e1. doi: 10.1053/j.gastro.2020.09.065.
Cedrón-Cheng H, Siccha Sinti C, Tagle Arróspide M. Mejora del curso clínico de la cirrosis hepática por virus de hepatitis C posterior al tratamiento efectivo con antivirales de acción directa. Rev Gastroenterol Peru. 2021;41(4):257-60. doi: 10.47892/rgp.2021.414.1350.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Jeffrey Freidenson-Bejar, Alvaro Bellido-Caparo, Martin Tagle
This work is licensed under a Creative Commons Attribution 4.0 International License.
Revista de Gastroenterología del Perú by Sociedad Peruana de Gastroenterología del Perú is licensed under a Licencia Creative Commons Atribución 4.0 Internacional..
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
2022 